## Galafold™ (migalastat) Referral Form

Email forms to: assist@amicusrx.com | Fax completed forms to: 1-833-264-2873

Questions? Call toll-free: 1-833-AMICUS-A (1-833-264-2872)

Please include copies of all insurance cards and print legibly, using blue or black ink.

This form serves a dual purpose. It allows patients to register for Amicus assist™ and also serves as a prescription for Galafold.

□ I opt not to enroll in Amicus assist at this time. I understand that this will not prohibit my receiving therapy with Galafold.

**Step 1:** Complete the following information to register the patient for Amicus assist.

This form will also act as a prescription and st	tatement of medical n	ecessity for Galafold.				
Patient Information (The correct patient infor to register the patient wit	mation is necessary fo th Amicus assist.)	r timely processing. Compl	ete all fields and provide acc	curate information		
First Name:	_ MI:	Last Name:				
Address 1:		Address 2:				
City: State:	_ Zip:	DOB:	Gender: □ Male □	Female		
Preferred Phone #:	Ca	n we leave a message on	this phone? ☐ Yes ☐	No		
Alternate Authorized Contact:		Phone #:				
Relationship to Patient:						
May an Amicus assist Case Manager contact the patient by email?		☐ Yes ☐ No Email:				
Preferred Method of Contact:		Preferred Time of Contact:				
Insurance Information (If available, photocopy the front and back of the patient's medical and prescription insurance cards and submit them with this form.)						
Primary Insurance:		Secondary Insurance:				
Policy Holder:		•				
Policy ID #:		Policy ID #:				
Group #:						
Phone #:		Phone #:				
Prescription Card (Name):		Phone #:				
Group #: ID #:						
Prescriber Information (Complete all inform	ation in this section as	it is essential for the Galaf	old prescription to be filled.	)		
First Name:		Last Name:				
Office/Institution:						
Address:						
City: State:	_ Zip:	Phone #	Fax #:			
Email: N						
Contact Person:						
Contact Phone # (direct):						
This section serves as a prescription for Galafol Any changes will require the submission of a ne				oduct access.		
Prescription Information: Galafold™ (migalastate ICD-10 Code: E75.21 Dosing Instructions: 123 mg PO (by mouth Dispensing Quantity:			taining 14 capsules)			
I certify that the above therapy is medically necessar my knowledge. I appoint Amicus assist, on my behalf named patient or to the dispensing pharmacy. I here mentioned patient to disclose the protected health on page 2 of the Galafold Referral Form. I also allow. The prescriber's signature is required to initiate re	, to provide this form by certify that my off information necessary Amicus assist to conta	or any information contained HIPAA-contained HIPAA-contained HIPAA-contained Amicus to provide seact the patient/caregiver and the patient and the p	ined on this form to the ins ompliant authorization fror prvices described in the Pati as needed to process this re	urer of the above n the above- ent Authorization		
Prescriber's Signature:			Date:			
(No Generic substitution permissible:	o stamped signatures p	ermitted.)				
•			Date:			
Prescriber's Signature:(No	o stamped signatures p	ermitted.)	Dale			

Instructions: Complete the Patient Authorization on page 2 and the Statement of Medical Necessity on page 3.

Please see the Important Safety Information on page 4 and the accompanying Full Prescribing Information including Patient Information and Instructions for Use.



## Galafold™ (migalastat) Referral Form

Email forms to: assist@amicusrx.com | Fax completed forms to: 1-833-264-2873

Questions? Call toll-free: 1-833-AMICUS-A (1-833-264-2872)

**Step 2:** Obtain patient authorization. Please have patient review and sign authorization below in order to enroll in Amicus assist™.

### Patient Authorization for Use and Disclosure of Health Information Pursuant to 45 C.F.R. §164.508

By signing this authorization ("Authorization"), I hereby certify and agree to the following:

I am (i) the Patient (identified in Step 1 above) and legally permitted to make decisions about how my health information is used and disclosed or (ii) the parent, legal guardian, or authorized representative of the Patient and legally permitted to make decisions about how the Patient's health information is used and disclosed.

I authorize my physician, identified on page 1 of this Referral Form, and their staff to disclose my health and other personal and protected health information, including but not limited to, the information on this Referral Form and information deemed relevant by my physician that may be considered sensitive or specially protected under state law, to Amicus and its agents and representatives (collectively "Amicus") so that Amicus may use and further disclose my information to healthcare providers, pharmacies, insurance companies, prescription drug plans, and other third-party payers (collectively, "Third Parties") in order to: (1) facilitate the filling of my prescription for and the delivery and administration of Galafold; (2) assist me in obtaining insurance coverage for Galafold; (3) contact me by mail, email, and/or telephone or text message to enroll me in, and administer, programs that provide Galafold support services; (4) contact me via those methods specified in (3) to provide me with free educational information and product materials; and/or (5) conduct quality assurance, surveys, and other internal business activities in connection with Galafold and Galafold support services; (6) address adverse events and product quality complaints.

I authorize my healthcare providers, including my physician identified on page 1 of this referral form, and their staff and my pharmacies to disclose my health and other personal and protected health information, including but not limited to the information about me in their possession, to Amicus in order to assist Amicus in accomplishing the purposes described above.

I understand that information disclosed pursuant to this Authorization could be re-disclosed by Recipients. Such re-disclosed information may no longer be protected by federal or state medical privacy laws, including the Health Insurance Portability and Accountability Act or "HIPAA."

I understand that I may refuse to sign this authorization and such refusal will not affect my ability to receive Galafold, my treatment, payment for treatment, enrollment in a health plan or eligibility for benefits, but it will limit my ability to receive support services for Galafold from Amicus.

This authorization will expire in 10 years after the date it is signed unless a shorter period is mandated by state law or I revoke or cancel my authorization by contacting Amicus in writing at:

### **ATTENTION: Amicus assist**

Amicus Therapeutics, Inc. 1 Cedar Brook Drive Cranbury, NJ 08512

If I revoke this authorization, Amicus will stop using and disclosing my information as soon as possible, but the revocation will not affect prior use or disclosure of my information in reliance on this authorization.

I understand that the services provided by Amicus that I have agreed to, and that are described in this authorization, may be reduced or terminated at any time, without prior notice.

I understand that my pharmacy, health insurer(s), or healthcare providers may receive remuneration from Amicus for disclosing pursuant to this authorization certain personal and medical information related to the Amicus assist activities conducted on my behalf so that Amicus may administer, assess and improve the quality of services being provided to patients. I also understand that my pharmacy may receive remuneration from Amicus for administering some of the services which are described above.

I have received a copy of this Authorization.

Patient's Signature	Date
P.C. of March Laws 50	
Patient's Name (please print)	
Patient's Authorized Representative (please print)	
Relationship to Patient	
Authorized Representative's Signature	 Date

The patient's signature is required to release his/her health information to Amicus assist and to open a dialogue about insurance.



# Galafold™ (migalastat) Referral Form

Email forms to: assist@amicusrx.com | Fax completed forms to: 1-833-264-2873

Questions? Call toll-free: 1-833-AMICUS-A (1-833-264-2872)

**Step 3:** Submit the completed form.

Statement of Medic	al Necessity – Galafold		
Patient Name/Inform	nation:		
First Name:	MI:	Last Name:	
DOB:			
Drug/Non-Drug Alle	ergies:		□ No known drug allergies
Diagnosis:			
Fabry Disease ICD-10	<b>Code:</b> E75.21		
Date of Diagnosis:			
Method of Diagnosis	(check all that apply):		
☐ Clinical signs	$\square$ $\alpha$ -Gal A enzyme activity levels	☐ Genotype	
☐ Other			
Amenable <i>GLA</i> Gene	Variant:		
□Yes □No	GLA Gene Variant:		
Clinical Signs and Syn	nptoms:		
Current/Prior Treatm	ent Plan:		
Therapy:		Dose:	
Date Initiated:	Date Discontinued (i	f applicable):	
Therapy:		Dose:	
Date Initiated:	Date Discontinued (i	f applicable):	
Other Medications: _			
to the best of my know	e therapy is medically necessary for the wledge. I appoint Amicus assist™, on my the above named patient or to the disp	behalf, to provide this form or any	•
Prescriber's Name (ple	ase print):	Date	e:
Prescriber's Signature:			
State License #:			

## Galafold™ (migalastat) Referral Form ∃

### **IMPORTANT SAFETY INFORMATION**

### **INDICATIONS AND USAGE**

GALAFOLD™ is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable alpha galactosidase A (GLA) gene variant based on *in vitro* assay data [see Clinical Pharmacology (12.1)].

This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

#### **ADVERSE REACTIONS**

The most common adverse reactions reported with GALAFOLD (≥10 %) were headache, nasopharyngitis, urinary tract infection, nausea, and pyrexia.

Please see accompanying Prescribing Information including Patient Information and Instructions for Use.

To report Suspected Adverse Reactions contact Amicus Therapeutics at 1-877-4AMICUS or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.



